Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Candida antigen - Nielson Biosciences

Next Previous
Drug Profile

Candida antigen - Nielson Biosciences

Alternative Names: Candida albicans antigen - Nielson Biosciences; Candida albicans skin test antigen - Nielson Biosciences; Candin

Latest Information Update: 07 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nielsen BioSciences
  • Developer Janssen Research & Development; Maruho; Nielsen BioSciences
  • Class Antigens; Diagnostic agents; Skin disorder therapies; Yeasts
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypersensitivity
  • Phase III Warts

Most Recent Events

  • 23 Oct 2025 Nielsen BioSciences expands licensing agreement with Maruho for the development and commercialisation of Candin in Asia Pacific, including China, South Korea, Taiwan, Hong Kong, Macau and several countries in the Association of Southeast Asian Nations (ASEAN)
  • 27 Aug 2025 Nielsen BioSciences completes a phase-III clinical trials in Warts (In adolescents, In adults, In the elderly) in USA and Japan (Intradermal) (NCT05889845)
  • 26 Feb 2025 Nielsen plans regulatory submissions for Warts (Intradermal) in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top